Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 versus topotecan or amrubicin for second-line small cell lung cancer
2012-004793-26Phase 3Terminated
- Sponsor
- Taiho Oncology
- Start
- Jan 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trifluridine + tipiracil, topotecan and amrubicin in small cell lung cancer (SCLC) (2 arms), sponsored by Taiho Oncology. Primary endpoint: Progression-free survival. Started Jan 2013; status: terminated.
02
Drugs
trifluridine + tipiraciltopotecanamrubicin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2012-004793-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004793-26.